
Oxular Ltd raises US$37m
Oxford-based Oxular said it will use the proceeds to finance Phase II studies evaluatingO the company’s lead asset, OXU-001, for the treatment of...

AZD1222 claims 79% effecacy in pivotal US study
For exactly one day, the belief that AstraZeneca's COVID-19 vaccine AZD1222 may be better than its reputation lasted. But because the ailing vaccine...

German Health Ministry to invest €6.2bn in vaccines
With the request to the national budget committee, which will decide on it tomorrow, Germany more than doubles the amount of money to be invested...

C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contract
The company's subsidiary C4X Discovery Ltd got €7m upfront with potential to gain €414m in total for the global commercialisation rights for its...

French biotech investors launch spin-out alliance
Argobio SAS has been kicked off with €50m of committed capital from Kurma Partners, and the state bank Bpifrance. Co-investors include Angelini...

Novel COVID antibody enters clinical testing
In contrast to existing COVID-19 treatments, the safety design of COR-101 is optimised for the treatment of hospitalized COVID-19 patients with...

MosaMeat BV closes US$85m Series B financing
While EU policymakers are yet discussing the green deal or farm to fork strategies, Dutch MosaMeat BV is launching a new era of biotechnologically...